Dataset Information


Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

ABSTRACT: Clinical studies converge on the observation that circulating cytokines are elevated in most cancer patients by anti-vascular endothelial growth factor (VEGF) therapy. However, the source of these molecules and their relevance in tumor escape remain unknown. We examined the gene expression profiles of cancer cells and tumor-associated macrophages in tumor biopsies before and 12 days after monotherapy with the anti-VEGF antibody bevacizumab in patients with rectal carcinoma. Bevacizumab up-regulated stromal cell-derived factor 1alpha (SDF1alpha), its receptor CXCR4, and CXCL6, and down-regulated PlGF, Ang1, and Ang2 in cancer cells. In addition, bevacizumab decreased Ang1 and induced neuropilin 1 (NRP1) expression in tumor-associated macrophages. Higher SDF1alpha plasma levels during bevacizumab treatment significantly associated with distant metastasis at three years. These data show that VEGF blockade up-regulates inflammatory pathways and NRP1, which should be evaluated as potential targets for improving anti-VEGF therapy.

PROVIDER: S-EPMC2859041 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5609745 | BioStudies
1000-01-01 | S-EPMC5107907 | BioStudies
2020-01-01 | S-EPMC7356919 | BioStudies
2017-01-01 | S-EPMC5491354 | BioStudies
| S-EPMC3160826 | BioStudies
2010-01-01 | S-EPMC2923676 | BioStudies
| S-EPMC6282968 | BioStudies
1000-01-01 | S-EPMC4718155 | BioStudies
2014-01-01 | S-EPMC4197402 | BioStudies
2017-01-01 | S-EPMC5624898 | BioStudies